EUROPEAN PRODUCERS FACE UNIQUE ISSUES - C&EN Global

Jan 17, 2005 - Industry insiders are concerned that not enough people skilled in science and engineering are entering the workforce. The plunging valu...
0 downloads 0 Views 2MB Size
Medicilon

Shanghai Medicilon Inc. Your partner in drug discovery and development

Shanghai Medicilon Inc. is a pharmaceutical R&D company that offers preclinical chemistry and pharmaceutical services to customers. Our chemistry

EUROPEAN PRODUCERS FACE UNIQUE ISSUES

• High throughput parallel synthesis

The dollar and other obstacles snarl the path to success of custom synthesis providers in Europe

• Custom synthesis of building blocks,

A. MAUREEN ROUHI, C&EN WASHINGTON

service programs integrate the expertise of our scientists in:

intermediates and reference compounds • Medicinal chemistry & lead optimization • Process research & scale up synthesis Our product development team proudly offers high quality products from mg-scale screening samples to kilo scale building blocks. Below are a few examples of products on kilo-scale: Ο

.Se^A0H

jj

Nf-L

For questions, contact Dr. Jintao Zhang Tel: +8621-51320238, +1 877 586-9267 FAX: +862151320222, www.medicilon.com E-mail: [email protected]

O

VER AND ABOVE THE BUSINESS

outlook that offers only cautious optimism for 2005, European producers must contend with other problems. The diminish­ ing dollar is wreaking havoc. A discrepan­ cy in regulatory requirements for suppli­ ers of active pharmaceutical ingredients (APIs) based outside Europe is under­ mining the competitiveness of those man­ ufacturing in Europe. Industry insiders are concerned that not enough people skilled in science and engineering are en­ tering the workforce. The plunging value of the dollar is a "nightmare," says Guy Villax, chief execu-

bases can meet such rising costs without drowning in red ink, he adds. The problem is mitigated by global pro­ duction facilities. "If you have sites in the U.S., India, or China, where costs are based in dollars, you produce there, you pay your costs in dollars, and you sell in dollars," ac­ cording to Ralf Pfirmann, senior vice pres­ ident and global business director for Clariant's pharmaceuticals business unit. "We are lucky that we have dollar-based sites," he adds, pointing to Clariant production fa­ cilities in Florida, South Carolina, and Mis­ souri. "But still we have a large footprint in Europe-based production." European producers really can't do

Request more at AdlnfoNow.org

MILD SELECTIVE FLUORINATING REAGENTS A VAILABLE IN BULK FROM FAR RESEARCH, INC.

F

·.

. ,- H " F

γ

\

H p

- -, . ,H-F

/

\

/

y

f -— HF-Base — - ?•

«